



Definitive Notice of the End Result

of the public tender offer by

Danaher Corporation, a Delaware corporation having its principal place of business in Washington, D.C., USA

for all publicly held registered shares with a nominal value of CHF 0.40 each of

Nobel Biocare Holding AG, Kloten, Switzerland

On 1 October 2014, Danaher Corporation, Washington, D.C., USA (**Danaher**), published the offer prospectus (the **Offer Prospectus**) for its public tender offer (the **Offer**) in accordance with article 22 et seq. of the Federal Stock Exchange and Securities Trading Act (*Bundesgesetz über die Börsen und den Effektenhandel*) for all publicly held registered shares of Nobel Biocare Holding AG, Kloten, Switzerland (**Nobel Biocare**), with a nominal value of CHF 0.40 each (each, a **Nobel Biocare Share**). The offer price for each Nobel Biocare Share amounts to CHF 17.10 net in cash, less the gross amount of any dilution effects becoming effective prior to the settlement of the Offer, as further described in the Offer Prospectus.

End Result

The participation of Danaher and the persons acting in concert with Danaher as of the end of the additional acceptance period on 4 December 2014, 4:00 p.m. CET (the **Additional Acceptance Period**), is 120,024,932 Nobel Biocare Shares in total, corresponding to 96.96% of the voting rights and the share capital of Nobel Biocare registered in the commercial register (participation rate), and consists of:

- a total of 91,123,722 Nobel Biocare Shares which were tendered into the Offer until the expiration of the Additional Acceptance Period, corresponding to 77.16% of the 118,095,706 Nobel Biocare Shares to which the Offer relates (success rate);
- 5,688,824 Nobel Biocare Shares which Danaher and the persons acting in concert with Danaher held as of 26 September 2014; and
- 23,212,386 Nobel Biocare Shares which Danaher and the persons acting in concert with Danaher purchased outside the Offer after such date until the expiration of the Additional Acceptance Period.

The following overview illustrates the end result:

	Number of Nobel Biocare Shares	Share capital/ Voting rights (participation rate)	Success rate
Nobel Biocare Shares tendered into the Offer	91,123,722	73.61%	77.16%
Nobel Biocare Shares held by Danaher and the persons acting in concert with Danaher as of 26 September 2014	5,688,824	4.60%	
Nobel Biocare Shares purchased by Danaher and the persons acting in concert with Danaher outside the Offer until the expiration of the Additional Acceptance Period	23,212,386	18.75%	
End result	120,024,932	96.96%	

Satisfaction of the Conditions

Except for condition (c) of the Offer, which remains in force until the settlement of the Offer, all conditions according to Section B.7 (*Conditions*) of the Offer Prospectus are satisfied. The settlement of the Offer will occur as planned (cf. below).

Settlement

The offer price for Nobel Biocare Shares which were validly tendered during the offer period and the Additional Acceptance Period will be paid on 11 December 2014.

Squeeze-out and De-listing

After completion of the Offer, as set out in Section E.3 (*Intentions of Danaher with respect to Nobel Biocare*) of the Offer Prospectus, Danaher intends to request the cancellation of the outstanding publicly held Nobel Biocare Shares, or to merge Nobel Biocare with a Swiss company directly or indirectly controlled by Danaher whereby the remaining shareholders will receive a compensation other than shares of the surviving Danaher entity, if permitted by law. Furthermore, after the Settlement Danaher intends to apply with SIX for the de-listing of the Nobel Biocare Shares in accordance with the listing rules of SIX and for an exemption of certain disclosure obligations under the listing rules of SIX until the date of de-listing of the Nobel Biocare Shares.

Offer Restrictions

The Offer is subject to the offer restrictions set forth in the Offer Prospectus. The Offer Prospectus may be obtained without delay and free of charge in German, French and English from Credit Suisse AG, Zurich (tel.: +41 (0)44 333 43 85; fax: +41 (0)44 333 35 93; e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and all other Offer documents are accessible under <http://phx.corporate-ir.net/phoenix.zhtml?c=82105&p=irol-irhome>.

Nobel Biocare Holding AG	Swiss Security Number	ISIN	Ticker Symbol
Registered shares not tendered (first trading line)	3785164	CH0037851646	NOBN
Registered shares tendered (second trading line)	25474182	CH0254741827	NOBNE

10 December 2014

Financial Advisor and Offer Manager

Credit Suisse